Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Rtw Biotech (RTW) Share News

IN BRIEF: RTW Biotech Opportunities extends buyback by USD15 million

20th Oct 2025 10:34

RTW Biotech Opportunities Ltd - Guernsey-based investor in life sciences sector - Adds USD15 million to share buyback programme, aiming to close the discount of its share price to net asset value. RTW Biotech has USD5.8 million to complete from its current USD30 million buyback and will top that up by USD15 million, which is equivalent to about 9.2 million shares. Funds for the buyback come from several recent realisations of portfolio holdings. The company's most recently report net asset value, as of June 30, was USD1.70. Read More

RTW Biotech invests USD7.4 million in financing round for Kailera

15th Oct 2025 13:17

(Alliance News) - RTW Biotech Opportunities Ltd said on Wednesday that it invested USD7.4 million in Kailera Therapeutics Inc for the company's USD600 million Series B financing round. Read More

Akero says new owner Novo Nordisk to drive commercialisation process

10th Oct 2025 11:58

(Alliance News) - Akero Therapeutics Inc on Friday said it will benefit from "industry-leading development capabilities and commercial infrastructure" through its acquisition by Novo Nordisk AS. Read More

IN BRIEF: RTW Biotech lifts NAV on Biogen's USD85 million Alcyone deal

23rd Sep 2025 11:01

RTW Biotech Opportunities Ltd - Guernsey, Channel Islands-based investor in high-growth life science sectors - Notes Biogen Inc's agreement announced last Thursday to acquire portfolio company Alcyone Therapeutics Inc for USD85 million upfront plus milestone payments. Says the deal represents a 242% uplift on RTW's USD2.1 million carrying value of Alcyone, adding USD5.0 million, or around 0.7%, to its August 31 NAV, where Alcyone represented approximately a 0.3% position. Alcyone is developing ThecaFlex DRx, an implantable device for intrathecal delivery of neurological therapies, which Biogen plans to deploy with its marketed drug Spinraza, with a launch targeted in 2028. The transaction its RTW's second portfolio takeout this year, following Merck & Co Inc's purchase of Verona Pharma PLC, and says it highlights embedded value in its private holdings. Read More

RTW Biotech Opportunities NAV falls in "volatile" period for biotech

11th Sep 2025 10:29

(Alliance News) - RTW Biotech Opportunities Ltd on Thursday said the biotech industry is navigating a "complex but increasingly constructive environment" as it reported a decline in its interim net asset value per share. Read More

IN BRIEF: RTW Biotech Opportunities joins FTSE all-share index

5th Sep 2025 09:27

RTW Biotech Opportunities Ltd - Guernsey, Channel Islands-based investor in high-growth life science sectors - Says it will join the FTSE all-share index on September 22. This follows FTSE Russell's decision to include securities trading in non-sterling currencies. Chair William Simpson says the move "is likely to enhance our exposure to investors, develop greater UK and international investor awareness of RTW Bio, and provide increased long-term access to capital." Read More

UK earnings, trading statements calendar - next 7 days

4th Sep 2025 14:26

Read More

RTW Biotech joins Aquestive funding to support oral epinephrine

19th Aug 2025 10:05

(Alliance News) - RTW Biotech Opportunities Ltd on Tuesday noted Aquestive Therapeutics Inc's announcement of a strategic funding agreement with funds managed by RTW Investments LP. Read More

Merck & Co snaps up respiratory drug maker Verona for USD10 billion

10th Jul 2025 09:06

(Alliance News) - Merck & Co Inc on Wednesday said it has struck a deal to acquire Verona Pharma PLC, bolstering its respiratory diseases offering. Read More

LONDON BRIEFING: Severn Trent "on track"; WPP makes non-exec next CEO

10th Jul 2025 07:53

(Alliance News) - Water utility Severn Trent and housebuilder Vistry backed guidance, while advertising firm WPP named a new chief executive. Read More

RTW Biotech hails Corxel obesity drug progress in US, China trials

24th Jun 2025 11:15

(Alliance News) - RTW Biotech Opportunities Ltd on Tuesday highlighted clinical developments from Corxel Pharmaceuticals (Shanghai) Co Ltd, its second-largest portfolio holding, including the start of a US phase 2 trial and positive results from a China study of Corxel's lead obesity treatment, CX11. Read More

UK shareholder meetings calendar - next 7 days

2nd Jun 2025 12:36

Read More

RTW Biotech notes mixed updates across portfolio companies

30th May 2025 12:35

(Alliance News) - RTW Biotech Opportunities Ltd on Friday provided updates on three of its key listed holdings, highlighting both promising clinical trial results and a significant setback involving one of its biotech investments. Read More

RTW Biotech investee sees encouraging results in cardiac disease trial

19th May 2025 14:20

(Alliance News) - RTW Biotech Opportunities Ltd on Monday noted investee Rocket Pharmaceuticals has reported "encouraging" data from a phase 1 clinical trial of its treatment for arrhythmogenic cardiomyopathy. Read More

RTW Biotech Opportunities notes positive trial data from investee

2nd May 2025 13:00

(Alliance News) - RTW Biotech Opportunities Ltd on Friday noted positive trial data from investee Artios Pharma, for the ongoing study of its lead candidate ART0380. Read More

RTW Biotech Opportunities closes new investment with Airna

3rd Apr 2025 17:23

(Alliance News) - RTW Biotech Opportunities Ltd on Thursday announced a new investment into biotech company Airna, closing its oversubscribed USD155 million series B financing round. Read More

RTW Biotech underperforms benchmark but optimistic for 2025

31st Mar 2025 13:32

(Alliance News) - RTW Biotech Opportunities Ltd on Monday said it underperformed its benchmarks during 2024, while total net asset value climbed following the takeover of Arix Bioscience PLC. Read More

UK earnings, trading statements calendar - next 7 days

24th Mar 2025 16:14

Read More

RTW Biotech notes positive data in Kailera Therapeutics obesity trial

27th Jan 2025 10:15

(Alliance News) - RTW Biotech Opportunities Ltd on Monday said portfolio company Kailera Therapeutics has received positive results from a recent weight loss treatment trial. Read More

RTW Biotech participates in investment rounds worth USD300 million

17th Jan 2025 11:26

(Alliance News) - RTW Biotech Opportunities Ltd on Friday said it has made two separate investments as part of series A and C funding rounds in two clinical-stage firms. Read More

FTSE 100 Latest
Value9,515.00
Change88.01